2022-08-02T08:17:57-05:00 2021-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2021-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET 9TH FL NEW YORK NY 10004 LOUIS D SCHWARTZ CFO 2128471111 2022-08-02 1 LOUIS SCHWARTZ 999009999 RICHARD J LOCASTRO CPA P00288314 3019519090 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z IAVI MARK FEINBERG 125 BROAD STREET 9TH FL NEW YORK NY 10004 145961580 0 X WWW.IAVI.ORG X 1996 DE TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS 15 14 227 16 0 0 88668597 124414676 7491603 1706926 725292 59888 226173 171108 97111665 126352598 20659666 26376831 0 0 36708551 39923469 0 0 383941 38699967 46851383 96068184 113151683 1043481 13200915 81721759 107049023 42470719 56078728 39251040 50970295 X A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, EMERGING INFECTIOUS DISEASES (INCLUDING COVID-19), AND NEGLECTED DISEASES. 0 0 96744308 25829759 1706926 RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS. THIS INCLUDES THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE THE HIV BURDEN IS GREATEST. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. 2408245 CONTRACT MANUFACTURING-RELATED ACTIVITIES: IAVI SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS. 1820742 547072 VACCINE ADVOCACY, PUBLIC AFFAIRS, AND POLICY: IAVI WORKS WITH POLICY MAKERS, ADVOCATES, AND REPRESENTATIVES OF THE COMMUNITIES WHERE DISEASE BURDEN IS GREATEST TO SUPPORT SCIENTIFIC RESEARCH AND DEVELOPMENT FOR ACCESSIBLE BIOMEDICAL PREVENTIVES AND TREATMENTS. 100973295 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 X 90 0 1 227 1 0 1 IN KE SF UK 0 0 0 0 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X X PATRICK MOUTON 2128471137 125 BROAD STREET 9TH FL NEW YORK NY 10004 MARK FEINBERG PRESIDENT/CEO 35.00 X X 646997 0 36716 ERIC PAUL GOOSBY BOARD CHAIR 2.00 X X 0 0 0 ANNE M VANLENT BOARD VICE CHAIR (UNTIL 12/2/21) 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD TREASURER 2.00 X X 0 0 0 LINDA-GAIL BECKER BOARD MEMBER 1.00 X 0 0 0 DAVID BLUMBERG BOARD MEMBER 1.00 X 0 0 0 JIM CONNOLLY BOARD MEMBER 1.00 X 0 0 0 MARK DYBUL BOARD MEMBER 1.00 X 0 0 0 WAFAA EL-SADR BOARD MEMBER (FROM 12/1/21) 1.00 X 0 0 0 FRANCINE NTOUMI BOARD MEMBER (UNTIL 12/2/21) 1.00 X 0 0 0 JOHN NKENGASONG BOARD MEMBER 1.00 X 0 0 0 ALEXIS M PINTO BOARD MEMBER (FROM 12/1/21) 1.00 X 0 0 0 JOHN W SHIVER BOARD MEMBER 1.00 X 0 0 0 SUSAN SILBERMANN BOARD MEMBER (FROM 12/1/21) 1.00 X 0 0 0 ANNE MARTIN SIMONDS BOARD MEMBER 1.00 X 0 0 0 RAJEEV VENKAYYA BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 35.00 X 509916 0 64942 LOUIS SCHWARTZ ASST. SEC. & CHIEF FINANCIAL OFFICER 35.00 X 368299 0 65639 FRANCES SINHA CHIEF PEOPLE OFFICER 35.00 X 343388 0 45818 LABEEB ABBOUD SEC. SR VP, GEN COUNS (UNTIL 7/31/21) 35.00 X 276345 0 44080 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINCES 35.00 X 464753 0 62532 SWATI GUPTA VP, EID & SCIENTIFIC STRATEGY 35.00 X 435928 0 77476 THOMAS HASSELL VP, VACCINE DEVELOPMENT R&D 35.00 X 396671 0 65639 WILLIAM BALLOU ADV SR SCI ADV/PROJ LEAD, HIV BNABS 35.00 X 362316 0 46801 DAGNA LAUFER VP & HEAD OF CLINICAL DEVELOPMENT 35.00 X 356214 0 32479 4160827 0 542122 119 0 1 0 EMMES CORPORATION 401 N WASHINGTON ST STE 700 ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 1145073 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA AS 3064 REGULATORY CONSULTANT 406450 US MEDICAL EQUIPMENT CONSULTANTS INC 5601 NW 72ND ST 324 OKLAHOMA CITY OK 73132 EQUIPMENT MAINTENANCE 344333 STRADLEY RONON STEVENS & YOUNG LLP 2005 MARKET ST 2600 PHILADELPHIA PA 19103 LEGAL SERVICES 276568 DUANE MORRIS LLP 30 SOUTH 17TH STREET PHILADELPHIA PA 191034196 LEGAL SERVICES 251941 7 X 77633796 46780880 124414676 CONTRACT SERVICE FEES 900099 1706926 1706926 1706926 613689 613689 19055181 19608982 -553801 -553801 -553801 MISCELLANEOUS 900099 171108 171108 171108 126352598 1706926 0 230996 7079271 7079271 19297560 19297560 2402142 171336 2230806 30069602 24968006 5084155 17441 2155033 1802125 351588 1320 3472726 2804372 666308 2046 1823966 1433075 389848 1043 694102 590849 103253 206275 206275 247500 247500 88275 88275 764774 169853 557421 37500 802164 513110 276561 12493 1785621 1359771 387769 38081 2858766 2636016 210918 11832 185820 162908 22912 218770 195705 23065 9393 9393 1393883 1346217 45172 2494 353209 261754 90598 857 RESEARCH&CLINICAL SVCS 28605150 27755445 849705 LAB SUPPLIES/EQUIPMENT 7943548 7943548 EQUIPMENT MAINT. 470231 385359 82469 2403 LICENSES & FEES 129632 20369 100332 8931 94270 76646 17624 113151683 100973295 11794447 383941 19388425 35825161 24820234 33286783 240821 891734 252300 198282 47881018 43993162 4025880 3887856 32786297 32733205 207802 226002 81721759 107049023 10744597 7483619 6236757 10451288 19197506 35515982 3497600 2794259 2627839 42470719 56078728 X 32976583 39462629 6274457 11507666 39251040 50970295 81721759 107049023 X 13200915 -1481660 X 0 1 X 1 1 1 X 79435403 75524844 84811837 88668597 124414676 452855357 79435403 75524844 84811837 88668597 124414676 452855357 147255787 305599570 596174 921661 1171355 741488 613689 4044367 234948 349691 1207878 226173 171107 2189797 459089521 10277434 0.66570 0.59620 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: WRITE OFF PROVISION FOR RISK - VAT REFUND - 2017 AMOUNT: $ 67,203. RE TAXES REFUND - 2018 AMOUNT: $ 38,091. 2019 AMOUNT: $ 30,000. OTHER INCOME - 2017 AMOUNT: $ 100,289. 2018 AMOUNT: $ 41,790. 2019 AMOUNT: $ 49,560. 2020 AMOUNT: $ 114,697. 2021 AMOUNT: $ 103,555. LOAN FORGIVENESS - 2017 AMOUNT: $ 67,456. 2018 AMOUNT: $ 78,810. 2019 AMOUNT: $ 59,169. 2020 AMOUNT: $ 63,601. 2021 AMOUNT: $ 67,552. ASSET TRANSFER CREDIT - 2018 AMOUNT: $ 191,000. 2019 AMOUNT: $ 942,000. 2020 AMOUNT: $ 47,875. BANK CREDIT - 2019 AMOUNT: $ 127,149. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 247500 247500 112904183 113151683 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 228050 267531 257550 247500 1000631 250000 250000 250000 250000 1000000 1500000 20081959 17683619 2398340 27799059 26309543 1489516 3887856 DEFERRED RENT 1575793 DEFERRED COMPENSATION PAYABLE 1052046 2627839 X 130781004 67151 4678212 4745363 126035641 88275 228682 316957 126352598 115268422 67151 4332699 4399850 110868572 88275 2194836 2283111 113151683 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2021, MANAGEMENT OF IAVI HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 3,521,713. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 103,869. REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 1,052,630. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 228,682. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 1,344,931. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 329,262. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 2,658,506. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT 2,194,836. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 7512787 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 469779 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 11314994 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 507291 EUROPE 1 8 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2223750 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2686018 SOUTH ASIA 1 23 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 4599676 SUB-SAHARAN AFRICA 1 41 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 924762 3 72 0 0 3 72 30239057 0 30239057 EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 4146817 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 1528321 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 674001 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 485862 WIRE TRANSFER 0 EUROPE RESEARCH & DEVELOPMENT 130715 WIRE TRANSFER 0 EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 547072 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1505477 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 2170733 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1501816 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1162294 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1548272 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1138159 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 895304 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 494164 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 442819 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 366519 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 89435 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 150844 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 117226 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 47644 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 35500 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 44208 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 74357 WIRE TRANSFER 0 22 1 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. PART III ACCOUNTING METHOD: 1 THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 2550777 0 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 771785 0 RESEARCH & DEVELOPMENT THE UNIVERSITY OF TEXAS MEDICAL BRANCH GALVESTON 301 UNIVERSITY BLVD GALVESTON TX 77555 746000949 501(C)(3) 695075 0 RESEARCH & DEVELOPMENT UNIVERSITY OF WISCONSIN-MADISON 21 N PARK STREET STE 6401 MADISON WI 537151218 366006492 501(C)(3) 482328 0 RESEARCH & DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 479606 0 RESEARCH & DEVELOPMENT TULANE UNIVERSITY THE ADMIN OF THE TULANE EDUCATIONAL FUND 6823 ST CHARLES AVE NEW ORLEANS LA 70118 720423889 501(C)(3) 427361 0 RESEARCH & DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910961784 501(C)(3) 367068 0 RESEARCH & DEVELOPMENT DAVID FITZ-PATRICK MD INC AKA EAST-WEST MEDICAL RESEARCH INSTITUTE 1585 KAPIOLANI BLVD SUITE 1500 HONOLULU HI 96814 651163705 OTHER 285045 0 RESEARCH & DEVELOPMENT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94158 943067788 501(C)(3) 195842 0 RESEARCH & DEVELOPMENT GEORGE WASHINGTON UNIVERSITY 45155 RESEARCH PLACE STE 160 ASHBURN VA 20147 530196584 501(C)(3) 190068 0 RESEARCH & DEVELOPMENT LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501(C)(3) 170126 0 RESEARCH & DEVELOPMENT BOSTON UNIVERSITY 881 COMMONWEALTH AVENUE BOSTON MA 02115 042103547 501(C)(3) 165566 0 RESEARCH & DEVELOPMENT BALLAD RESEARCH INSTITUTE 10865 ROAD TO THE CURE SUITE 100 SAN DIEGO CA 92121 463097024 501(C)(3) 68292 0 RESEARCH & DEVELOPMENT EMMES CORPORATION 401 N WASHINGTON STREET SUITE 700 ROCKVILLE MD 20850 541058268 501(C)(3) 64996 0 RESEARCH & DEVELOPMENT NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 62564 0 RESEARCH & DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH 503 ROBERT GRANT AVENUE SILVER SPRING MD 20910 530196956 501(C)(3) 39334 0 RESEARCH & DEVELOPMENT THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER SA 7703 FLOYD CURL DRIVE SAN ANTONIO TX 782293900 741586031 501(C)(3) 30766 0 RESEARCH & DEVELOPMENT FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 26372 0 RESEARCH & DEVELOPMENT ICHOR - ICHOR MEDICAL SYSTEMS 6310 NANCY RIDGE DR 107 SAN DIEGO CA 92121 330636813 OTHER 6300 0 RESEARCH & DEVELOPMENT 17 2 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X 0 0 0 0 0 0 0 1 0 MARK FEINBERG PRESIDENT/CEO 588107 0 54904 0 3986 0 31900 0 4816 0 683713 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 466372 0 43264 0 280 0 31900 0 33042 0 574858 0 0 0 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINCES 326942 0 135331 0 2480 0 31900 0 30632 0 527285 0 0 0 SWATI GUPTA VP, EID & SCIENTIFIC STRATEGY 347481 0 87100 0 1347 0 31900 0 45576 0 513404 0 0 0 THOMAS HASSELL VP, VACCINE DEVELOPMENT R&D 356335 0 38062 0 2274 0 31900 0 33739 0 462310 0 0 0 LOUIS SCHWARTZ ASST. SEC. & CHIEF FINANCIAL OFFICER 334569 0 31385 0 2345 0 31900 0 33739 0 433938 0 0 0 WILLIAM BALLOU ADV SR SCI ADV/PROJ LEAD, HIV BNABS 330080 0 28385 0 3851 0 31900 0 14901 0 409117 0 0 0 FRANCES SINHA CHIEF PEOPLE OFFICER 310673 0 32100 0 615 0 31900 0 13918 0 389206 0 0 0 DAGNA LAUFER VP & HEAD OF CLINICAL DEVELOPMENT 320380 0 34600 0 1234 0 31900 0 579 0 388693 0 0 0 LABEEB ABBOUD SEC. SR VP, GEN COUNS (UNTIL 7/31/21 231893 0 41537 0 2915 0 25094 0 18986 0 320425 0 0 0 PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). CHRISTOPHER PARKS AND SWATI GUPTA RECEIVED A SUPPLEMENTAL BONUS OF $100,000 AND $50,000 RESPECTIVELY FOR WORK DONE IN CONNECTION WITH THE DEVELOPMENT OF COVID VACCINE CANDIDATES WHICH WERE SUBSEQUENTLY LICENSED TO A THIRD PARTY. THESE BONUSES ARE IN RECOGNITION OF THE CONTRIBUTION PARKS AND GUPTA MADE FOR THIS PROGRAM. DECISION TO GRANT THESE SUPPLEMENTAL BONUSES WAS REVIEWED AND APPROVED BY THE COMPENSATION COMMITTEE OF IAVI'S BOARD OF DIRECTORS, AND SUBSEQUENTLY SHARED WITH THE ENTIRE BOARD OF DIRECTORS. NOODLE FOX MEDIA THE OWNER OF THE ENTITY IS A FAMILY MEMBER (SPOUSE) OF AN OFFICER OF IAVI. 23550 IAVI HAS A CONSULTING AGREEMENT WITH NOODLE FOX MEDIA, TO PROVIDE MANAGING EDITOR SERVICES FOR IAVI REPORT. THE CONSULTANT WAS SELECTED ON A SOLE SOURCE BASIS, DUE TO UNIQUE SKILL AND EXPERIENCE. THE CONSULTANT HAD PREVIOUSLY SERVED AT IAVI AS MANAGING EDITOR FOR IAVI REPORT, AND BROUGHT RELEVANT SUBSTANTIVE KNOWLEDGE, SCIENTIFIC CONTACTS, AND EXPERTISE IN SCIENCE WRITING, EDITING AND MANAGING THE PUBLICATION PROCESS. THE AGREEMENT WAS ESTABLISHED ON AN ARMS-LENGTH BASIS BY THE ORGANIZATION. 0 DESMOND TUTU HIV FOUNDATION AN IAVI BOARD MEMBER IS THE DEPUTY DIRECTOR AND COO OF THE ENTITY. 67414 IAVI HAS A SUB-AWARD AGREEMENT WITH DESMOND TUTU INSTITUTE FOR HIV RESEARCH FOUNDATION. 0 FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE CONTROLLER AND CFO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD PERIODICALLY COMMISSIONS A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. THE SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THE COMMITTEE REVIEWS THE RESULTS OF THE SURVEY AND RECOMMENDATIONS MADE, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI ENGAGES AN EXTERNAL SPECIALIZED FIRM WITH EXPERTISE TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN MARCH 2021. IN CONJUNCTION WITH THE CEO'S COMPENSATION REVIEW, THE COMPENSATION COMMITTEE OF THE BOARD ALSO COMMISSIONS AN EXTERNAL COMPARATIVE COMPENSATION SURVEY OF ORGANIZATIONS SIMILAR TO IAVI, IN WHICH THE COMPENSATION PACKAGES OF ALL OTHER OFFICERS AND KEY EMPLOYEES ARE BENCHMARKED AGAINST THE LABOR MARKET TO DETERMINE APPROPRIATENESS OF PAY. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THIS SURVEY AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, ONCE EVERY 2 YEARS IAVI COMMISSIONS A COMPENSATION SURVEY, ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. THE RESULTS OF EACH SURVEY ARE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART VIII, LINE 1E ON APRIL 22, 2020, IAVI RECEIVED LOAN PROCEEDS IN THE AMOUNT OF $3,429,355 UNDER THE PAYCHECK PROTECTION PROGRAM. THE PROMISSORY NOTE INITIALLY CALLED FOR MONTHLY PRINCIPAL AND INTEREST PAYMENTS AMORTIZED OVER THE TERM OF THE PROMISSORY NOTE WITH A DEFERRAL OF PAYMENTS FOR THE FIRST SIX MONTHS. UNDER THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT (CARES ACT), THE PROMISSORY NOTE MAY BE FORGIVEN BY THE SMALL BUSINESS ADMINISTRATION IN WHOLE OR IN PART. ON JUNE 5, 2020, THE PAYCHECK PROTECTION PROGRAM FLEXIBILITY ACT OF 2020 (FLEXIBILITY ACT) WAS SIGNED INTO LAW, AMENDING THE CARES ACT, INCLUDING THE FIRST PAYMENT DATE. ON SEPTEMBER 20, 2021, THE LOAN AMOUNT OF $3,429,355 WAS FULLY FORGIVEN. THE REVENUE FROM DEBT EXTINGUISHMENT IS RECORDED UNDER OTHER INCOME IN THE ACCOMPANYING CONSOLIDATED STATEMENT OF ACTIVITIES AND CHANGE IN NET ASSETS. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE LOSS -852,329. DE-OBLIGATION OF FUNDS -629,331. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 2056283 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI SOUTH AFRICA NPC (IAVI-SA) BLACK RIVER PARK 2 FIR ST OBSERVA CAPETOWN SF RESEARCH SUPPORT SF N/A N/A IAVI INC 1 IAVI HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262032322 HOLDING COMPANY DE IAVI INC C 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 547072 ACTUAL IAVI-SA B 1548272 ACTUAL